Cyclacel Capital Stock vs Total Assets Analysis

CYCC Stock  USD 0.40  0.01  2.56%   
Cyclacel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cyclacel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclacel Pharmaceuticals is a good investment. Please check the relationship between Cyclacel Pharmaceuticals Capital Stock and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.

Capital Stock vs Total Assets

Capital Stock vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclacel Pharmaceuticals Capital Stock account and Total Assets. At this time, the significance of the direction appears to have no relationship.
The correlation between Cyclacel Pharmaceuticals' Capital Stock and Total Assets is 0.09. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Total Assets in the same time period over historical financial statements of Cyclacel Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cyclacel Pharmaceuticals' Capital Stock and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Cyclacel Pharmaceuticals are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Capital Stock i.e., Cyclacel Pharmaceuticals' Capital Stock and Total Assets go up and down completely randomly.

Correlation Coefficient

0.09
Relationship DirectionPositive 
Relationship StrengthInsignificant

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Total Assets

Total assets refers to the total amount of Cyclacel Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cyclacel Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Cyclacel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclacel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.At present, Cyclacel Pharmaceuticals' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 5.9 M.
 2023 2024 (projected)
Discontinued Operations17.1K30.4K
Cost Of Revenue28.8K27.4K

Cyclacel Pharmaceuticals fundamental ratios Correlations

0.570.230.15-0.340.010.020.14-0.060.00.180.13-0.69-0.320.830.09-0.020.940.090.090.12-0.080.00.930.110.09
0.57-0.53-0.72-0.030.72-0.8-0.690.21-0.69-0.52-0.73-0.980.020.92-0.58-0.370.790.27-0.3-0.73-0.03-0.630.82-0.730.02
0.23-0.530.83-0.67-0.930.80.91-0.190.720.690.860.37-0.4-0.190.370.040.050.130.610.84-0.470.6-0.040.86-0.24
0.15-0.720.83-0.24-0.850.970.97-0.410.770.820.990.6-0.36-0.410.780.38-0.15-0.270.431.0-0.060.8-0.210.990.02
-0.34-0.03-0.67-0.240.45-0.16-0.42-0.03-0.19-0.42-0.290.140.47-0.250.160.51-0.36-0.44-0.37-0.270.76-0.23-0.28-0.280.29
0.010.72-0.93-0.850.45-0.88-0.90.21-0.76-0.68-0.87-0.590.350.44-0.47-0.170.21-0.02-0.58-0.860.31-0.680.3-0.880.22
0.02-0.80.80.97-0.16-0.880.93-0.30.840.750.970.69-0.26-0.530.790.46-0.28-0.280.420.970.020.78-0.330.970.04
0.14-0.690.910.97-0.42-0.90.93-0.450.720.850.990.57-0.43-0.380.620.16-0.12-0.160.470.98-0.310.8-0.20.99-0.15
-0.060.21-0.19-0.41-0.030.21-0.3-0.450.22-0.57-0.44-0.240.570.14-0.290.250.020.27-0.04-0.430.28-0.560.09-0.440.22
0.0-0.690.720.77-0.19-0.760.840.720.220.410.750.560.17-0.440.570.58-0.26-0.130.390.760.10.43-0.270.760.09
0.18-0.520.690.82-0.42-0.680.750.85-0.570.410.840.46-0.69-0.270.69-0.09-0.05-0.210.320.84-0.260.96-0.130.83-0.11
0.13-0.730.860.99-0.29-0.870.970.99-0.440.750.840.61-0.38-0.420.730.29-0.16-0.240.451.0-0.160.81-0.231.0-0.07
-0.69-0.980.370.60.14-0.590.690.57-0.240.560.460.610.02-0.970.540.32-0.88-0.310.180.620.070.6-0.910.62-0.01
-0.320.02-0.4-0.360.470.35-0.26-0.430.570.17-0.69-0.380.02-0.15-0.280.42-0.27-0.05-0.28-0.380.38-0.61-0.18-0.370.17
0.830.92-0.19-0.41-0.250.44-0.53-0.380.14-0.44-0.27-0.42-0.97-0.15-0.41-0.30.960.28-0.09-0.43-0.13-0.440.97-0.43-0.01
0.09-0.580.370.780.16-0.470.790.62-0.290.570.690.730.54-0.28-0.410.61-0.23-0.470.190.760.480.74-0.230.720.43
-0.02-0.370.040.380.51-0.170.460.160.250.58-0.090.290.320.42-0.30.61-0.24-0.280.130.330.79-0.01-0.170.30.6
0.940.790.05-0.15-0.360.21-0.28-0.120.02-0.26-0.05-0.16-0.88-0.270.96-0.23-0.240.230.04-0.17-0.19-0.240.99-0.17-0.03
0.090.270.13-0.27-0.44-0.02-0.28-0.160.27-0.13-0.21-0.24-0.31-0.050.28-0.47-0.280.230.58-0.25-0.32-0.290.21-0.24-0.15
0.09-0.30.610.43-0.37-0.580.420.47-0.040.390.320.450.18-0.28-0.090.190.130.040.580.44-0.120.29-0.050.45-0.1
0.12-0.730.841.0-0.27-0.860.970.98-0.430.760.841.00.62-0.38-0.430.760.33-0.17-0.250.44-0.110.82-0.241.0-0.01
-0.08-0.03-0.47-0.060.760.310.02-0.310.280.1-0.26-0.160.070.38-0.130.480.79-0.19-0.32-0.12-0.11-0.12-0.1-0.150.61
0.0-0.630.60.8-0.23-0.680.780.8-0.560.430.960.810.6-0.61-0.440.74-0.01-0.24-0.290.290.82-0.12-0.310.81-0.14
0.930.82-0.04-0.21-0.280.3-0.33-0.20.09-0.27-0.13-0.23-0.91-0.180.97-0.23-0.170.990.21-0.05-0.24-0.1-0.31-0.240.05
0.11-0.730.860.99-0.28-0.880.970.99-0.440.760.831.00.62-0.37-0.430.720.3-0.17-0.240.451.0-0.150.81-0.24-0.08
0.090.02-0.240.020.290.220.04-0.150.220.09-0.11-0.07-0.010.17-0.010.430.6-0.03-0.15-0.1-0.010.61-0.140.05-0.08
Click cells to compare fundamentals

Cyclacel Pharmaceuticals Account Relationship Matchups

Cyclacel Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets15.3M36.8M42.6M27.5M8.8M8.4M
Total Stockholder Equity11.7M33.3M37.3M15.5M607K576.7K
Retained Earnings(357.6M)(366.1M)(385.0M)(406.2M)(428.3M)(406.9M)
Common Stock Shares Outstanding54.4K242.2K595.1K657.6K850.8K893.4K
Liabilities And Stockholders Equity15.3M36.8M42.6M27.5M8.8M8.4M
Other Stockholder Equity370.1M400.1M423.0M414.0M429.8M284.3M
Total Liab3.6M3.5M5.3M12.0M8.2M14.1M
Other Current Liab1.5M2.0M3.2M4.8M4.6M3.4M
Total Current Liabilities2.4M2.5M5.3M7.4M8.2M5.8M
Property Plant And Equipment Net1.3M1.3M94K174K102K96.9K
Net Debt(10.7M)(32.3M)(36.5M)(18.2M)(3.3M)(3.5M)
Accounts Payable890K514K2.1M2.6M3.5M2.2M
Cash11.9M33.4M36.6M18.3M3.4M3.2M
Non Current Assets Total1.3M1.3M1.6M3.1M1.4M1.7M
Non Currrent Assets Other(1.3M)(1.3M)1.6M2.9M1.3M1.3M
Cash And Short Term Investments11.9M33.4M36.6M18.3M3.4M3.2M
Non Current Liabilities Total1.2M1.1M30K4.6M37K35.2K
Other Current Assets103K750K4.4M6.1M4.1M4.3M
Property Plant And Equipment Gross1.3M1.3M94K174K522K839.0K
Total Current Assets14.0M35.5M40.9M24.4M7.4M7.1M
Accumulated Other Comprehensive Income(819K)(746K)(748K)(1.3M)(908K)(953.4K)
Common Stock17K6K10K4.5M1K950.0
Net Receivables1.3M1.3M3.7M5.6M2.9M2.7M
Inventory703K684K577K(5.6M)(5.1M)(4.8M)
Property Plant Equipment27K106K94K174K156.6K148.8K
Retained Earnings Total Equity(342.5M)(349.8M)(357.6M)(366.1M)(329.5M)(345.9M)
Net Tangible Assets11.7M33.3M37.3M15.5M17.8M23.9M
Capital Surpluse365.1M365.8M370.1M400.1M460.1M394.6M
Non Current Liabilities Other124K100K1.2M1.1M1.2M1.3M
Net Invested Capital11.7M33.3M37.3M20.0M607K576.7K
Net Working Capital11.6M33.0M35.6M17.0M(717K)(681.2K)
Capital Stock17K6K10K4.5M1K950.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cyclacel Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclacel Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclacel Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclacel Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclacel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(27.40)
Revenue Per Share
0.044
Quarterly Revenue Growth
(0.99)
Return On Assets
(1.03)
Return On Equity
(5.71)
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.